Literature DB >> 17400672

Atrial septostomy decreases sympathetic overactivity in pulmonary arterial hypertension.

Agnieszka Ciarka1, Jean-Luc Vachièry, Anne Houssière, Marko Gujic, Eric Stoupel, Sonia Velez-Roa, Robert Naeije, Philippe van de Borne.   

Abstract

BACKGROUND: We have reported previously that the sympathetic nervous system is activated in patients with pulmonary arterial hypertension (PAH), and that this is only partly explained by a decrease in arterial oxygenation. Possible causes for increased muscle sympathetic nerve activity (MSNA) in patients with PAH include right atrial distension and decreased cardiac output. Both may be improved by atrial septostomy, but this intervention also further decreases arterial oxygenation. In the present study, we wanted to investigate the effect of atrial septostomy on MSNA in patients with PAH.
METHODS: We recorded BP, heart rate (HR), arterial O2 saturation (SaO2), and MSNA before and after atrial septostomy in PAH patients (mean [+/- SE] age, 48 +/- 5 years) and in closely matched control subjects. Measurements were also performed after septostomy, while SaO2 was brought to the preprocedure level by supplemental O2 therapy.
RESULTS: Compared to the control subjects (n = 10), the PAH patients (n = 11) had a lower mean BP (75 +/- 2 vs 96 +/- 3 mm Hg, respectively; p < 0.001), lower mean SaO2 (92 +/- 1% vs 97 +/- 0%, respectively; p < 0.001), increased mean HR (84 +/- 4 vs 68 +/- 3 beats/min; p < 0.01), and markedly increased mean MSNA (76 +/- 5 vs 29 +/- 2 bursts per minute; p < 0.001). Atrial septostomy decreased mean SaO2 (to 85 +/- 2%; p < 0.001) and mean MSNA (to 69 +/- 4 bursts per minute; p < 0.01), but did not affect HR or BP. Therapy with supplemental O2 did not affect MSNA, BP, or HR. The decrease in MSNA was correlated to the decrease in right atrial pressure (r = 0.62; p < 0.05).
CONCLUSIONS: Atrial septostomy in PAH patients decreases sympathetic hyperactivity despite an associated decrease in arterial oxygenation, and this appears to be related to decreased right atrial distension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400672     DOI: 10.1378/chest.06-2903

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  15 in total

Review 1.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

2.  Kinetics of skeletal muscle O2 delivery and utilization at the onset of heavy-intensity exercise in pulmonary arterial hypertension.

Authors:  Priscila B Barbosa; Eloara M V Ferreira; Jaquelina S O Arakaki; Luciana S Takara; Juliana Moura; Rúbia B Nascimento; Luiz E Nery; J Alberto Neder
Journal:  Eur J Appl Physiol       Date:  2011-01-12       Impact factor: 3.078

3.  Nerve distribution of canine pulmonary arteries and potential clinical implications.

Authors:  Yun Zhang; Weijie Chen; Yanping Xu; Hang Liu; Yunlin Chen; Hanxuan Yang; Yuehui Yin
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 4.  Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?

Authors:  Sergio Caravita; Jean-Luc Vachiéry
Journal:  Curr Heart Fail Rep       Date:  2016-12

5.  Impact of differential right-to-left shunting on systemic perfusion in pulmonary arterial hypertension.

Authors:  Timo Weimar; Yoshiyuki Watanabe; Toshinobu Kazui; Urvi S Lee; Alessandro Montecalvo; Richard B Schuessler; Marc R Moon
Journal:  Catheter Cardiovasc Interv       Date:  2012-11-14       Impact factor: 2.692

Review 6.  Sympathetic and Vagal Nerve Activity in COPD: Pathophysiology, Presumed Determinants and Underappreciated Therapeutic Potential.

Authors:  Jens Spiesshoefer; Binaya Regmi; Matteo Maria Ottaviani; Florian Kahles; Alberto Giannoni; Chiara Borrelli; Claudio Passino; Vaughan Macefield; Michael Dreher
Journal:  Front Physiol       Date:  2022-06-23       Impact factor: 4.755

7.  Diminazene aceturate improves autonomic modulation in pulmonary hypertension.

Authors:  Katya Rigatto; Karina R Casali; Vinayak Shenoy; Michael J Katovich; Mohan K Raizada
Journal:  Eur J Pharmacol       Date:  2013-05-09       Impact factor: 4.432

8.  Exercise intolerance in pulmonary arterial hypertension.

Authors:  Robin M Fowler; Kevin R Gain; Eli Gabbay
Journal:  Pulm Med       Date:  2012-06-10

Review 9.  Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Matthew Levy; Olusegun Oyenuga
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

10.  The von Hippel-Lindau Chuvash mutation in mice alters cardiac substrate and high-energy phosphate metabolism.

Authors:  Mary Slingo; Mark Cole; Carolyn Carr; Mary K Curtis; Michael Dodd; Lucia Giles; Lisa C Heather; Damian Tyler; Kieran Clarke; Peter A Robbins
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-15       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.